IT
The startup develops anti-infective therapies that target priority pathogens to combat antibiotic resistance and improve patient outcomes. Its portfolio includes both acquired and internally developed drugs designed to meet critical needs in managing pandemics and infectious diseases.
Updated 3 months ago
Funding
$9.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops anti-infective therapies that target priority pathogens to combat antibiotic resistance and improve patient outcomes. Its portfolio includes both acquired and internally developed drugs designed to meet critical needs in managing pandemics and infectious diseases.